About Us

Roger holds strong leadership to develop & sustain an aggressive & profitable strategy for Stelis in its core areas. Roger is a seasoned professional in the biopharmaceutical space with rich experience in developing & executing strategies related to innovative biologics, biosimilars, CDMOs & complex injectable products. In his diverse career of 30+ years, he has held senior leadership positions in Allergan, Cytovance Biologics, KBI Biopharma, Diosynth RTP (formerly Covance Biotechnology Services) & Lonza Biologics. He has a strong track record in start-ups & entrepreneurial environments in overseeing operations, executing commercial strategies, & driving contract process development.

Before Stelis, Roger was the President, CEO & Member of the Board at Avid Bioservices, Inc., a California based publicly listed biotech R&D Company which, in his leadership, had a successful transition to a dedicated biologics CDMO with a strong financial & business performance. Roger is a Graduate in Physiology & Biochemistry from the University of Southampton, United Kingdom & has earned his PhD in Biotechnology from the University of Cambridge, United Kingdom.

Raghavendra is a strategic HR Leader with over two decades of cross-sectoral experience. He held many positions in manufacturing, engineering, automotive, apparel, footwear, semiconductor, IT and R&D at most recognized Indian organizations and some of the most prominent brands world over. His expertise spans over the entire HR value chain with strong grasp of business and organizational fundamentals. He has a stellar track record of impacting and transforming organizations & individuals by driving business aligned Strategic HR and influence business outcomes

Before joining Stelis, he was associated with Siemens as President – HR and Head of Learning and Development. He has also worked in leadership capacity with Organizations like, Tata Motors, NXP Semiconductors, ABB Global, Volvo India. He has Post Graduate Diploma in Personnel Management from National Institute of Personnel Management, India and was a Research Scholar in Organizational Behaviour at XLRI Jamshedpur.

A Chartered Accountant and a Company Secretary by qualification, Paresh comes with overall 22 years of experience in multiple industries and geographies. Prior to joining Stelis, he was with GVK Bio Group of Companies, a private equity funded research and development organisation having multiple BUs and operating subsidiaries in US and Europe, as their CFO. Previously he has worked at Jubilant Drax Image Inc. Canada as VP -Finance, Fisher Biopharma Services (India) Pvt Ltd, as Director Finance, Lufthansa Technik, as CFO & Company Secretary, Kraft Foods, as Finance Controller & Company Secretary, Esab India Limited, as GM Finance, Hindustan Construction Company Limited, as Manager- Accounts & Finance, and Eureka Forbes Limited as Executive-Internal Audit. Paresh has varied experience in both manufacturing as well as service organisations.

He has been awarded with Role of Honor by CFO100 for 3 consecutive years in 2017, 2018 & 2019. He is regularly invited as an expert speaker in various Industry forums and conferences.

Anand was instrumental in setting up a world class protein formulation & analytics group at Biocon. He has over 22 year’s experience in research & has led CMC development of several biosimilars (MABs, Insulin analogues) & novel molecules as per the requirements of global regulatory bodies. His expertise includes process development, scale up, technology transfer, troubleshooting formulation development & protein analytical development & characterization. He was the innovator for oral insulin (Insulin Tregopil) at Biocon & led the program from lab to advanced clinical development, leading a large cross-functional team.

At Apobiologix, Anand was involved in mentoring a team of scientists engaged in biosimilar development; developing strategies for biosimilars, antibody drug conjugates, & high concentration formulation of MABs; evaluating CROs & CDMOs; & performing due diligence of biosimilar products for in-licensing. He was also involved in developing an oncology product on a 505( b)(2) pathway. Anand has a Ph.D in protein formulation & characterization from Deakin University, Australia & a master’s degree from the Institute of Chemical Technology, India in Bioprocess Development.

Vishvesh comes with over 28 years of international working experience in leading biopharmaceutical companies and academic institutions.

Prior to joining Stelis, he was with Dr. Reddy’s Laboratories, Hyderabad as Vice President – Quality and Partner Operations, Biologics Division since 2011 where he was instrumental in establishing a Quality Function, designed and rolled out an efficient Quality Management to enable the integration of quality throughout the product lifecycle, leveraged the Strategy Deployment Process (SDP) framework for designing and enabling processes for anytime audit readiness and successfully lead Biologics Business Unit in over 40 National and International Regulatory Audits.

Previously he was with Bayer Healthcare, Berkeley/Emeryville, CA, USA as Deputy/Associate Director – QC Biological Operations, University of California Berkeley, CA, USA as Staff Scientist Environmental Engineering and Post-Doctoral Researcher. He was also associated with LBNL, Berkeley, CA, USA, University of Oklahoma, OK, USA, and University of Tulsa, OK, USA.

Vishvesh has completed his Ph.D. in Microbiology (University of Oklahoma, Oklahoma, USA) and Post-Doctorate in Environmental Engineering (University of California, Berkeley, USA.

Milan has over 2 decades of experience in creating business values in Biotech and Pharmaceutical industry worldwide. Before venturing into Business Development activities, he worked as an Engineer on project for setting up one of the biggest IV fluid facility.

Prior to joining Stelis, he was Director of Business Development at Apotex and worked for companies like Mabxience and Intas where he established global presence for Biosimilars in regulated and emerging markets. Milan has been instrumental in successfully concluding more than 70 licensing collaboration agreements covering Biosimilars, Biologics and Specialty Pharmaceuticals across North America, Japan, China, Russia, South East Asia, Europe and Middle East. At Stelis his goal is to establish global footprints of Stelis products. He holds Bachelor’s degree in Engineering and MBA in Finance and Marketing.